EP1881828A4 - Treatment of hcv with subtherapeutic doses of ribavirin - Google Patents

Treatment of hcv with subtherapeutic doses of ribavirin

Info

Publication number: EP1881828A4
Authority: EP; European Patent Office
Prior art keywords: ribavirin; hcv; treatment; subtherapeutic doses; subtherapeutic
Prior art date: 2005-05-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP06759554A

Other languages

German (de)

French (fr)

Other versions

EP1881828A1 (en

Inventor

Zhi Hong

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Valeant Research and Development

Original Assignee

Valeant Research and Development

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-20

Filing date

2006-05-09

Publication date

2009-06-03

2006-05-09 Application filed by Valeant Research and Development filed Critical Valeant Research and Development

2008-01-30 Publication of EP1881828A1 publication Critical patent/EP1881828A1/en

2009-06-03 Publication of EP1881828A4 publication Critical patent/EP1881828A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP06759554A 2005-05-20 2006-05-09 Treatment of hcv with subtherapeutic doses of ribavirin Withdrawn EP1881828A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US68341605P	2005-05-20	2005-05-20
PCT/US2006/018228 WO2006127289A1 (en)	2005-05-20	2006-05-09	Treatment of hcv with subtherapeutic doses of ribavirin

Publications (2)

Publication Number	Publication Date
EP1881828A1 EP1881828A1 (en)	2008-01-30
EP1881828A4 true EP1881828A4 (en)	2009-06-03

Family

ID=37452331

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP06759554A Withdrawn EP1881828A4 (en)	2005-05-20	2006-05-09	Treatment of hcv with subtherapeutic doses of ribavirin

Country Status (2)

Country	Link
EP (1)	EP1881828A4 (en)
WO (1)	WO2006127289A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
UY34402A (en)	2011-10-21	2013-05-31	Abbvie Inc	METHODS FOR HCV TREATMENT
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
CN104023726A (en)	2011-10-21	2014-09-03	艾伯维公司	Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
CA2863645A1 (en) *	2012-02-01	2013-08-08	Samuel Waksal	Once daily treatment of hepatitis c with ribavirin and taribavirin
US11192914B2 (en)	2016-04-28	2021-12-07	Emory University	Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998017679A1 (en) *	1996-10-18	1998-04-30	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2000024725A1 (en) *	1998-10-26	2000-05-04	Vertex Pharmaceuticals Incorporated	Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
WO2003101199A1 (en) *	2002-05-31	2003-12-11	Schering Corporation	Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
WO2006007693A1 (en) *	2004-07-16	2006-01-26	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
WO2006039488A2 (en) *	2004-10-01	2006-04-13	Vertex Pharmaceuticals Incorporated	Hcv ns3-ns4a protease inhibition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2480583C (en) *	2002-04-01	2008-07-15	Pfizer Inc.	Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase

2006
- 2006-05-09 WO PCT/US2006/018228 patent/WO2006127289A1/en active Application Filing
- 2006-05-09 EP EP06759554A patent/EP1881828A4/en not_active Withdrawn

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998017679A1 (en) *	1996-10-18	1998-04-30	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2000024725A1 (en) *	1998-10-26	2000-05-04	Vertex Pharmaceuticals Incorporated	Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
WO2003101199A1 (en) *	2002-05-31	2003-12-11	Schering Corporation	Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
WO2006007693A1 (en) *	2004-07-16	2006-01-26	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
WO2006039488A2 (en) *	2004-10-01	2006-04-13	Vertex Pharmaceuticals Incorporated	Hcv ns3-ns4a protease inhibition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KATO ET AL: "Steroid-Free Induction and Preemptive Antiviral Therapy for Liver Transplant Recipients With Hepatitis C: A Preliminary Report from a Prospective Randomized Study", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, vol. 37, no. 2, 18 April 2005 (2005-04-18), pages 1217 - 1219, XP022309764, ISSN: 0041-1345 *
NAKA K ET AL: "Mizoribine inhibits hepatitis C virus RNA replication: Effect of combination with interferon-alpha", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 330, no. 3, 13 May 2005 (2005-05-13), pages 871 - 879, XP004833719, ISSN: 0006-291X *
See also references of WO2006127289A1 *

Also Published As

Publication number	Publication date
EP1881828A1 (en)	2008-01-30
WO2006127289A1 (en)	2006-11-30

Legal Events

Date	Code	Title	Description
2007-12-28	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2008-01-30	17P	Request for examination filed	Effective date: 20071031
2008-01-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2008-08-27	DAX	Request for extension of the european patent (deleted)
2009-06-03	A4	Supplementary search report drawn up and despatched	Effective date: 20090508
2009-06-03	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/21 20060101ALI20090430BHEP Ipc: A61P 31/14 20060101ALI20090430BHEP Ipc: A61K 31/4196 20060101AFI20061215BHEP
2009-10-14	17Q	First examination report despatched	Effective date: 20090911
2012-06-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2012-07-04	18D	Application deemed to be withdrawn	Effective date: 20120110

Publication	Publication Date	Title
ZA200703908B (en)	2009-06-24	Compositions for HCV treatment
AP2907A (en)	2014-05-31	Viral hepatitis treatment
HK1124241A1 (en)	2009-07-10	Azaindazole compounds and therapeutic uses thereof
HK1168104A1 (en)	2012-12-21	Spiro-oxindole compounds and their uses as therapeutic agents
EP1849835A4 (en)	2011-02-09	Organic-inorganic composite body
ZA200710551B (en)	2008-11-26	Use of sanglifehrin in HCV
EP1729713A4 (en)	2009-06-10	Hydrotherapy vessel
GB0500843D0 (en)	2005-02-23	Rotary massaging rack
AP2009004840A0 (en)	2009-04-30	Compounds and methods for treatment of HCV
PL1867241T3 (en)	2013-12-31	Seasoning having function of imparting body
IL211810A0 (en)	2011-06-30	Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis
EP1881828A4 (en)	2009-06-03	Treatment of hcv with subtherapeutic doses of ribavirin
IL180487A0 (en)	2007-06-03	Medicament
GB0526120D0 (en)	2006-02-01	Therapeutic peptides
IL169322A0 (en)	2007-07-04	Hcv combination therapy
AU306220S (en)	2006-03-29	Massage chair
GB0410502D0 (en)	2004-06-16	Treatment of metakaolin
IL188962A0 (en)	2008-08-07	Peg-ifn alpha and ribavirin for hbv treatment
GB0426141D0 (en)	2004-12-29	Treatment
GB0425854D0 (en)	2004-12-29	Therapeutic treatment
ZA200902434B (en)	2010-09-29	Compounds and methods for treatment of HCV
GB0408752D0 (en)	2004-05-26	Therapeutic treatment
GB0426942D0 (en)	2005-01-12	Medicament
GB0409098D0 (en)	2004-05-26	Medicament
GB0617310D0 (en)	2006-10-11	Treatment of hepatitis c